ClinicalTrials.gg
RecruitingNCT07661706Updated Aug 26, 2026

Data Collection of New Spectral CT Imaging Method

An observational study in Computed Tomography, sponsored by GE Healthcare. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by GE Healthcare · Observational

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to collect data to evaluate utility of a next generation spectral CT system in a clinical setting.

Read the detailed description

Data collected in this study includes an assessment of image quality parameters to evaluate the product. This data and analysis will help support regulatory submissions.

02

Conditions studied

  • Computed Tomography
03

In context

Lead sponsor

GE Healthcare is the lead sponsor of 176 studies on the registry; 21 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The subject population will consist of adults that are 18-years of age or older who in the past 90 days or will in the future 30 days of the investigational scan undergo a clinically indicated CT exam within the St. Luke's University Hospital Network of the neck, chest, abdomen, pelvis, or extremities.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Who are ≥18 years of age;
  • Able to sign and date the form; AND,
  • Who have in the past 90 days or will in the future 30 days of the scan undergo a clinically indicated CT exam within the St. Luke's University Hospital Network of the neck, chest, abdomen, pelvis, or extremities.

Exclusion criteria

Exclusion Criteria:

  • Who are pregnant or lactating;
  • Who were previously enrolled in this study;
  • For planned contrast-enhanced CT exams, anyone with known or suspected allergy to iodinated contrast agents;
  • For planned contrast-enhanced investigational CT exams, anyone with known or suspected renal insufficiency as determined by site medical personnel;
  • Who need urgent or emergent care;
  • Who have any conditions that, in the opinion of the PI or designee, would interfere with the evaluation of the results or constitute a health hazard for the subject; OR,
  • Who are unwilling to have GEHC personnel present for the CT exam.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Research CT

    Device: Research CT

Interventions

  • DeviceResearch CT

    Participants will undergo a research CT on an investigational Spectral CT Imaging scanner which will be matched to their prior or scheduled SOC CT. Scans will be matched on anatomy, radiation dose, and contrast administration.

06

What researchers measure

Primary outcomes

  1. Evaluable Raw Research Scans

    Number of participants who research scan is deemed evaluable (i.e., no issues with participant motion or contrast administration/timing)

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Safety Assessment

    Number of Adverse Events and/or Serious Adverse Events reported.

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07661706
Lead sponsor
GE Healthcare
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Dec 19, 2025
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Aug 26, 2026

Study contacts

Melissa Challman, MPH, CCRP
Contact
melissa.challman@gehealthcare.com
18582213007
Brian Thomsen
study director · GE Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion